<DOC>
	<DOCNO>NCT02615860</DOCNO>
	<brief_summary>Comparative evaluation efficacy safety high-resolution anoscopy ( HRA ) -guided topical treatment ( trichloroacetic acid , TCA ) vs. surgical treatment ( electrocautery , ECA ) HIV-positive patient human papillomavirus ( HPV ) - induce AIN , anal cancer precursor . The primary hypothesis cost-saving simple TCA treatment non-inferior current best option therapy ECA . TCA treatment would also possible normal set doctor´s office without extensive specialization without complex technical equipment .</brief_summary>
	<brief_title>Efficacy Safety TCA vs. ECA Treatment AIN HIV-positive Patients</brief_title>
	<detailed_description>Anal human papillomavirus ( HPV ) -infection HPV-induced AIN , anal cancer precursor , frequent HIV-positive patient ( HIV+ ) , especially men sex men ( MSM ) , also woman . Consequently , HIV+ strongly increase risk anal cancer . Screening treatment AIN recommend HIV+ , although two RCT AIN treatment publish . We plan multicenter , unblinded , non-inferiority RCT evaluate efficacy safety 2 high-resolution anoscopy ( HRA ) -guided treatment option AIN : topical application trichloroacetic acid ( TCA ) surgical treatment electrocautery ( ECA ) . ECA best option intra-anal AIN recent randomize control trial ( RCT ) . TCA , inexpensive establish therapy genital wart , evaluate AIN retrospective pilot study show clearance rate comparable found ECA , possibly less adverse event ( AE ) . Our primary hypothesis cost-saving simple TCA non-inferior ECA . 2800 HIV+ screen HRA 9 proctological center 560 HIV+ histologically confirm intra-anal AIN randomize ( 1:1 ) receive 4 treatment TCA ECA within 12 week . The primary efficacy endpoint clinical ( HRA ) histological resolution AIN 4 week last treatment . Secondary endpoint comprise recurrence AIN 24 week end therapy , number intervention , AE , influence HPV parameter anal HPV-types , viral load HPV-oncogene-mRNA .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<criteria>HIV positive patient Legally eligible patient age ≥ 18 year Sufficient knowledge German language , speak write Patient willing able appear regularly treatment followup appointment Clinically visible AINlesion , confirm histopathology ( finding older 2 week date collection removal date longer 16 week prior baseline ) Written informed consent Currently diagnose anal cancer anal cancer anamnesis ( within last 5 year ) Acute lifethreatening disease Participation proctologic study within last 30 day Participation study earlier date Simultaneous participation another clinical trial , exclude participation study Simultaneous topical systemic treatment wtih medication affect study outcome , immunomodulatory substance : Interferone , imiquimod systemic glucocorticosteroids lactation Pregnancy : In patient childbearing age , pregnancy rule pregnancy test suitable method . Women childbearing potential without adequate contraceptive protection . Contraindication use trichloroacetic acid electrocautery Patients general anesthesia treatment AIN necessary already study start Other serious intraanal proctologic disorder , make additional proctologic systemic treatment necessary , influence study result , active Crohn 's disease , must treat locally systemically immunosuppressives active proctitis . Patients vaccinate baseline HPV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HIV-infection</keyword>
	<keyword>anal cancer ( AC )</keyword>
	<keyword>anal cancer prevention</keyword>
	<keyword>anal dysplasia</keyword>
	<keyword>anal intraepithelial neoplasia ( AIN )</keyword>
	<keyword>human papillomavirus ( HPV )</keyword>
	<keyword>HPV-induced anal cancer precursor lesion</keyword>
	<keyword>electrocautery ( ECA )</keyword>
	<keyword>topical trichloroacetic acid ( TCA ) treatment .</keyword>
</DOC>